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Background: Mycoplasma pneumoniae (Mpn) is a human pathogen that causes acute and chronic respiratory
diseases and has been linked to many extrapulmonary diseases. Due to the lack of cell wall, Mpn is resistant to
antibiotics targeting cell wall synthesis such as penicillin. During the last 10 years macrolide-resistant Mpn strains
have been frequently reported in Asian countries and have been spreading to Europe and the United States.
Therefore, new antibiotics are needed. In this study, 30 FDA-approved anticancer or antiviral drugs were screened
for inhibitory effects on Mpn growth and selected analogs were further characterized by inhibition of target
enzymes and metabolism of radiolabeled substrates.
Results: Sixteen drugs showed varying inhibitory effects and seven showed strong inhibition of Mpn growth. The
anticancer drug 6-thioguanine had a MIC (minimum inhibitory concentration required to cause 90% of growth
inhibition) value of 0.20 μg ml-1, whereas trifluorothymidine, gemcitabine and dipyridamole had MIC values of
approximately 2 μg ml-1. In wild type Mpn culture the presence of 6-thioguanine and dipyridamole strongly
inhibited the uptake and metabolism of hypoxanthine and guanine while gemcitabine inhibited the uptake and
metabolism of all nucleobases and thymidine. Trifluorothymidine and 5-fluorodeoxyuridine, however, stimulated the
uptake and incorporation of radiolabeled thymidine and this stimulation was due to induction of thymidine kinase
activity. Furthermore, Mpn hypoxanthine guanine phosphoribosyl transferase (HPRT) was cloned, expressed, and
characterized. The 6-thioguanine, but not other purine analogs, strongly inhibited HPRT, which may in part explain
the observed growth inhibition. Trifluorothymidine and 5-fluorodeoxyuridine were shown to be good substrates
and inhibitors for thymidine kinase from human and Mycoplasma sources.
Conclusion: We have shown that several anticancer and antiviral nucleoside and nucleobase analogs are potent
inhibitors of Mpn growth and that the mechanism of inhibition are most likely due to inhibition of enzymes in the
nucleotide biosynthesis pathway and nucleoside transporter. Our results suggest that enzymes in Mycoplasma
nucleotide biosynthesis are potential targets for future design of antibiotics against Mycoplasma infection.
Keywords: Mycoplasma pneumoniae, Growth inhibition, 6-thioguanine, Trifluorothymidine, Hypoxanthine guanine
phosphoribosyl transferase, Thymidine kinaseBackground
Mycoplasmas are wall-less, gram-positive bacteria and are
pathogenic to humans, animals, and plants [1].Mycoplasma
pneumoniae (Mpn) is a human pathogen and causes acute
and chronic diseases at multiple sites. Respiratory diseases
dominate and account for approximately 30% of cases of* Correspondence: liya.wang@slu.se
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reproduction in any medium, provided the orcommunity-acquired pneumonia. Mpn may also be a direct
cause or significant cofactor in many extrapulmonary dis-
eases including rheumatoid arthritis, and central nerve
system manifestations such as encephalitis, aseptic menin-
gitis, acute transverse myelitis, stroke, chronic fatigue, and
polyradiculopathy [1-3]. Due to the lack of cell wall, Mpn
is resistant to antibiotics targeting cell wall synthesis such
as penicillin, and macrolides are the treatment of choice.
Increased incidences/epidemics of Mpn infections have
been reported in Scandinavian countries, France, Scotland,ral Ltd. This is an Open Access article distributed under the terms of the Creative
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infected individuals did not need medical attention. How-
ever, approximately 10% of the patients developed pneu-
monia and antibiotic treatment was needed. In severe
cases, hospitalization was required and there were lethal
cases when patients were infected by macrolide-resistant
Mpn strains [6,7]. During the last 10 years macrolide-
resistant Mpn strains have been frequently reported in
Asian countries and have been spreading to Europe and
the United States. In Japan and China, approximately
90% of the isolates are resistant to erythromycin or
azithromycin, especially among pediatric patients [8-12].
This limits treatment options for patients with severe
Mycoplasma pneumonia caused by macrolide resistant
Mpn strains. Therefore, new antibiotics are needed.
Nucleotides are not only the building blocks of DNA
and RNA, but also regulatory factors in diverse cellular
metabolic pathways, and therefore, inhibition of enzymes
in this pathway will cause nucleotide pool imbalance,
which will inhibit DNA and RNA synthesis and lead to
cell death. When transported into and metabolized by
cells, nucleoside analogs can interfere with metabolism
of natural nucleotides and/or DNA and RNA synthesis.
An example of this type of antibiotic is sulphonamides
such as sulfamethoxazole that target dihydropteroate syn-
thetase in the folic acid biosynthesis pathway, and inhib-
ition of folic acid biosynthesis leads to impaired purine
and pyrimidine nucleotide biosynthesis [13]. Another
example is thymidylate synthase (TS) inhibitors such as
Ralitrexed and 5-fluorouracil used as anticancer drugs
[14,15]. Today more than 50% of the United States Food
and Drug Administration (FDA)-approved anticancer
and antiviral drugs are nucleoside and nucleobase ana-
logs. The most successful reports since the 1970s, using
nucleoside analogs as drugs, were for the treatment of
herpes viral infections by acyclic guanosine analogs
such as acyclovir, and HIV infection by nucleoside
analogs such as Zidovudine or Lamivudine in combination
with protease inhibitors i.e., highly active antiretroviral
therapy [16,17].
Compared to other antibacterial compounds, most
nucleoside and nucleobase analogs used in anticancer
and antiviral therapy have narrow therapeutic index and
adverse side effects, with the exception of acyclic guano-
sine analogs used in the treatment of herpes viral infec-
tion. These adverse effects limit their use in the treatment
of bacterial infections. In recent years efforts have been
made to develop nucleoside analog based antibiotics,
taking the advantage of structural differences in target
enzymes between bacteria and their host to design and
select specific inhibitors that will selectively kill the bac-
teria and spare the host [18-23]. For example, selective
thymidylate kinase inhibitors have been developed and
showed potent inhibitory effect in vivo against methicillin-resistant Staphylococcus aureus and vancomycin-resistant
Enterococcus [22,23]. Toxicity or side effect of these thymi-
dylate kinase inhibitors to humans remains to be seen.
Mycoplasmas, in general, depend on exogenous supply
of precursors for their nucleotide biosynthesis because
they lack the de novo synthesis of purine and pyrimidine
bases. Nucleosides and deoxynucleosides are efficiently
taken up and phosphorylated to their respective nucleo-
tides by deoxynucleoside kinases such as thymidine kinase
(TK) and deoxyadenosine kinase. Nucleobases are salvaged
through hypoxanthine guanine phosphoribosyltransferase
(HPRT), adenine phosphoribosyltransferase (APRT) and
uracil phosphoribosyltransferase (UPRT) systems [24-32].
Of a total of 17 enzymes in nucleotide biosynthesis
identified in the Mpn genome, 15 are essential. Enzymes
mentioned above, TK, HPRT, APRT and UPRT are essen-
tial for Mpn survival while thymidylate synthase (TS), an
enzyme catalyses the reductive synthesis of thymidylate
from uridylate, is not since thyA mutant Mpn strain that
lacks TS is viable [31,33,34].
In this study, 30 FDA-approved nucleoside and nucleo-
base analogs that are anticancer or antiviral drugs were
screened for inhibitory effects on Mpn growth. Seven
analogs showed potent inhibitory effects on Mpn growth
at clinically achievable plasma concentrations. Among
them, 6-thioguanine (6-GT) inhibited Mpn growth with
a MIC (minimum inhibitory concentration required to
cause 90% of growth inhibition) value of 0.20 μg ml-1.
To investigate the mechanism of action of these drugs,
we studied the effects of these analogs on uptake and
metabolism of natural nucleoside and nucleobases by
using tritium labelled natural substrates. Furthermore
Mpn hypoxanthine guanine phosphoribosyl transferase
(HPRT) was cloned and expressed, and the recombinant
enzyme was purified and characterized using tritium
labelled hypoxanthine and guanine as substrates, and
6-thiuoguanine and other purine analogs as inhibi-
tors. The role of thymidine kinase in the inhibitory
effect of trifluorothymidine against Mpn growth was
also investigated.
Results
Inhibition of Mpn growth by nucleoside and
nucleobase analogs
Some nucleoside analogs have been reported to inhibit
Mycoplasma growth [30,35]. Recently a nucleoside and
nucleobase analog library consisting of FDA-approved
prodrugs used in anticancer and antiviral therapy was
used to screen human enzymes in nucleotide metabolism,
and new interactions were found [36], which promoted
the use of these analogs in screening for inhibitory effects
on Mpn growth. A series dilution of each compound in
Mycoplasma growth medium was added to Mpn cultures
in 96-well plates. The plates were sealed and incubated
Table 1 Inhibition of M. pneumoniae growth by
nucleoside and nucleobase analogs*




Ribavirin 62.5 > 500
Pentoxifylline 62.5 > 500
Gancyclovir 7.8 > 500
Zidovudine 7.8 7.8
Gemcitabine (dFdC) 2.4 2.4
Stavudine 7.8 17.8
Acyclovir 15.6 15.6
Pyrimethamine > 500 > 500
Fludarabine phosphate > 500 > 500
Lamivudine > 500 > 500
Mycophenolate mofetil 250 250
Trifluorothymidine (TFT) 1.8 1.8
Adefovir depivoxil > 500 > 500
5-azacytidine > 500 > 500
Azathioprine > 500 > 500
Arabinosyl adenine > 500 > 500
Zalcitabine > 500 > 500
5-iododeoxyuridine 15.6 > 500
5-fluorodeoxyuridine (5FdU) 7.8 15.6
Cidofovir 31.2 31.2
Caffeine > 500 > 500
7-(2,3-dihydroxypropyl)theophylline > 500 > 500
Theophylline > 500 > 500
6-thioguanine (6-TG) 0.2 0.2
Allopurinol > 500 > 500
6-mercaptopurine (6-MP) > 500 > 500
5-fluorouracil 31.2 31.2
5-fluorocytosine 31.2 31.2
Valacyclovir > 500 > 500
Dipyridamole 1.9 1.9
*MIC = minimal concentrations of the compound that produced 90% inhibition.
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index value e.g. the ratio of absorbance at 450 nm and
560 nm of the culture medium [32]. Thirty nucleoside
and nucleobase analogs and a nucleoside transporter
inhibitor were included, and two Mpn strains, wild type
and a thyA mutant (lacking TS activity), were used.
Sixteen of these compounds inhibited Mpn growth to
varying levels, and seven showed strong inhibition (Table 1).
The anticancer drug 6-TG and the antiviral and anti-
cancer drug trifluorothymidine (TFT) strongly inhibited
Mpn growth, with MIC values of 0.2 μg ml-1 and 1.8 μg ml-1,
respectively. Gemcitabine (dFdC), an anticancer agent,
was also strong inhibitor of Mpn growth with MIC of
approximately 2.5 μg ml-1. Dipyridamole, a nucleoside
transporter inhibitor, also strongly inhibited Mpn
growth with MIC of 1.9 μg ml-1 (Table 1). All analogs
had MIC values at clinically achievable plasma concen-
trations. The cultures were kept for additional 3 weeks
in the incubator and there was no indication of growth.
For most compounds, the inhibitory effects were similar
between the wild type and the thyA mutant Mpn strains,
however differences between the two Mpn strains were
also observed. For example, gancyclovir inhibited wild
type Mpn but not the thyA mutant, whereas valacyclovir
did not inhibit Mpn growth. Ribavirin and pentoxifylline
inhibited wild type Mpn but not the thyA mutant. Among
the 5-halogenated pyrimidine analogs, most of them
inhibited both the wild type and the thyA mutant strain,
but 5-iododeoxyuridine only inhibited the wild type Mpn
growth (Table 1).
Uptake and metabolism of natural nucleosides and
nucleobases in the presence of analogs
To investigate the mechanism of inhibition by these
analogs, we incubated Mpn wild type cells with radio-
labelled natural substrates in the presence and absence of
those analogs that strongly inhibited Mpn growth. Total
uptake and metabolism of the radiolabelled substrates were
analysed to access whether the observed growth inhibition
is at the level of nucleoside transporter or metabolism or
both (Table 2). In general the uptake of nucleobases e.g.
[3H]-Ade (adenine), [3H]-Gua (guanine), [3H]-Ura (uracil),
and [3H]-Hx (hypoxanthine) was low (< 1%) as compared
with that of [3H]-dT (thymidine) (> 7%). Dipyridamole
strongly inhibited the uptake and incorporation of [3H]-Hx
and [3H]-Gua into DNA and RNA but had no effect on up-
take and metabolism of all other nucleobases and [3H]-dT,
suggesting that dipyridamole is a specific inhibitor of
purine transport. Similar to dipyridamole, 6-TG also
strongly inhibited the uptake and incorporation of [3H]-Hx
and [3H]-Gua into DNA and RNA but had no effect on
any other nucleobases and dT. Pyrimidine nucleoside
analogs, TFT, 5FdU (5-fluorodeoxyuridine) and dFdC,
inhibited the uptake and incorporation of all nucleobases.However, [3H]-dT uptake was stimulated (2-fold) by TFT
and 5FdU but inhibited by dFdC, and the percentage of
radioactivity found in DNA was similar to that of control
in all cases (Table 2). These results indicate that there are
distinct transporters for purines and pyrimidines and that
metabolic rate determines the extent of uptake.
Up-regulation of Mpn TK activity by TFT
To understand why TFT and 5FdU stimulated [3H]-dT
uptake, Mpn wild type cells were incubated with various
concentrations of TFT in the presence of [3H]-dT. Total
proteins were extracted from these cultures and used to
determine the TK and TS activity. Total uptake of [3H]-dT
increased in a concentration dependent manner while
the percentage of [3H]-dT found in DNA was similar.
Table 2 Inhibition of tritium labelled natural nucleoside and nucleobase uptake and metabolism by selected analogs*
[3H]-dT [3H]-Ura [3H]-Hx [3H]-Gua [3H]-Ade
Total uptake Incorporation Total uptake Incorporation Total uptake Incorporation Total uptake Incorporation Total uptake Incorporation
None 7.6±0.5 97.5±0.5 0.20±0.003 40±5 0.050± 0.001 62±7 0.9±0.05 56±3 0.62±0.1 44±1
Dipyridamole 7.2±1.1 97.0±1.3 0.20±0.003 38±6 0.008± 0.001 44±3 0.09±0.002 56±6 0.67±0.1 47±1
6-TG 7.9±0.6 97.4±0.7 0.21±0.003 39±8 0.005 ± 0.0004 43±6 0.080±0.002 67±3 0.66±0.1 46±3
TFT 18.2±0.6 97.4±0.5 0.11±0.002 27±0.2 0.011± 0.001 67±1 0.19±0.02 85±4 0.43±0.01 48±2
5FdU 14.7±0.2 96.0±0.5 0.087±0.003 19±7 0.006± 0.001 76±4 0.16±0.03 87±3 0.36±0.1 42±2
dFdC 5.2±0.4 96.7±1.1 0.12±0.001 26±6 0.009±0.0002 67±7 0.10±0.02 90±6 0.41±0.08 39±8
*Total uptake: percentage of radioactivity recovered in the cells divided by total radioactivity added to the growth medium.




















Figure 2 Substrate saturation curves of hypoxanthine (A) and
guanine (B) with Mpn HPRT. Kinetic parameters for Hx and Gua
were determined by using the DE81 filter paper assay with [3H]-Hx
and [3H]-Gua as the labelled substrates as described in the
experimental procedures. Data are from at least three independent
measurements and are presented as mean ± standard deviation (SD).
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increases and with 10 μM TFT the TK activity was ~ 3
times of the activity found in the controls. TS activity,
however, was unchanged (Figure 1). These results dem-
onstrated that TFT induced up-regulation of TK activity
but had no effect on TS activity, and suggested that the
high level of dT uptake in the presence of TFT and
5FdU is due to increased TK activity.
Expression, purification, and characterization of HPRT
The purine analog 6-TG strongly inhibited Mpn growth,
which promoted further investigation of potential targets
of this compound. HPRT is the first enzyme in the sal-
vage pathway of purine bases for nucleotide biosynthesis,
and is the enzyme responsible for metabolizing 6-TG in
human patients treated with this drug [37]. Mpn HPRT
(MPN672) consists of 175 amino acids and shares 29%
sequence identity to human HPRT. Mpn HPRT cDNA
was cloned and expressed in E. coli. Recombinant Mpn
HPRT was expressed as an N-terminal fusion protein
with a 6 × histidine tag and a tobacco etch virus (TEV)
cleavage site at the N-terminus, and was purified to >98%
purity by metal affinity chromatography, as assessed by
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) analysis (data not shown).
The purified Mpn HPRT used both hypoxanthine (Hx)
and guanine (Gua) as substrates but not adenine or
uracil. With Hx as substrate the reaction was linear with
time for up to 25 min and the substrate saturation curve
was hyperbolic, which indicated that the enzyme followed
Michaelis–Menten kinetics with a Km value of 100.1 ±
6.5 μM and Vmax value of 15.8 ± 0.8 μmol min
-1 mg-1
(Figure 2A). However, with Gua as a substrate, the
reverse reaction rate was very high and the reaction
reached equilibrium in less than 5 min under the sameFigure 1 The effect of trifluorothymidine (TFT) on the uptake of
[3H]-dT (●), TK (■) and TS (▲) activity. Mpn wild type cells were
cultured in the presence of [3H]-dT and different concentrations of
TFT. The cells were incubated at 37°C for 70 hours and harvested.
The total uptake and incorporation of [3H]-dT were analysed, and TK
and TS activity were determined in total protein extracts.conditions used for Hx. Therefore, the kinetic study
with Gua was conducted differently as described in the
experimental procedures. Substrate saturation for Gua
exhibited a biphasic curve and therefore, data was fit-
ted using the Hill equation. The Vmax value was 2.7 ±
0.1 μmol min-1 mg-1 and S0.5 was 107.6 ± 6.2 μM with
a Hill coefficient of 3.5 (Figure 2B), indicating positive
cooperativity with Gua binding.
Inhibition of Mpn and human HPRT with 6-TG and other
purine analogs
To study the mechanism of inhibition by 6-TG on Mpn
growth, we determined the inhibitory effect of 6-TG,
6-mercaptopurine (6-MP), and two other purine ana-
logs that did not inhibit Mpn growth on Mpn HPRT,
and compared the results with human HPRT. The 6-TG
strongly inhibited Mpn HPRT with either Hx or Gua as a
substrate, and the half maximal inhibitory concentration
(IC50) values were 3.5 ± 0.5 μM (Hx) and 3.2 ± 0.2 μM
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a much higher IC50 value (Table 3). The 6-MP inhibited
Mpn HPRT with IC50 values of 89.7 ± 14.5 μM (Hx)
and 281.9 ± 21 μM (Gua). With human HPRT, 6-MP
had similar IC50 values to those of 6-TG. Theophylline
and caffeine were poor inhibitors of both Mpn and hu-
man HPRT (Table 3).
Trifluorothymidine (TFT) as substrate for human
thymidine kinase (TK) 1, TK2, and Ureaplasma TK
TFT is a known substrate of human TK1, and has been
used as an antiviral and anticancer drug. We found that
TFT strongly inhibited Mpn growth, suggesting that Mpn TK
may have a role in growth inhibition caused by TFT. The
mechanism of inhibition by TFT and 5-fluorodeoxyuridine
(5FdU) was proposed to be linked to inhibition of TS [38].
However, we observed that TFT and 5FdU inhibited both
the wild type and the thyA mutant strains to similar
extents, suggesting that the mechanism of inhibition is
unlikely to be solely by inhibition of TS activity. Therefore,
we sought to characterize TFT phosphorylation by Myco-
plasma TK and compared this with the human enzymes.
Kinetic studies with TFT were performed with purified
recombinant human TK1 (a cytosolic enzyme), TK2
(a mitochondrial isoenzyme), and UreaplasmaTK. Because
Ureaplasma TK and Mpn TK share 46% sequence identity
and they also share 36% respective 32% sequence identity
to human TK1 [30,39], and Mpn TK is not available.
The phosphorylation of TFT by human TK1, TK2, and
Ureaplasma TK followed Michaelis-Menten kinetics and
the Km values for the three enzymes were in the same
range, while the kcat values varied between the three
enzymes (Figure 3). Ureaplasma TK had the highest kcat
value and human TK2 had the lowest kcat value (Table 4).
However, the overall efficiency was highest with human
TK1 and lowest with human TK2 (Table 4).
Inhibition of human TK1, TK2, and Ureaplasma and Mpn
TK by TFT and 5FdU
Both TFT and 5FdU are substrates of Mycoplasma and hu-
man TKs, as described above and earlier studies [30,40,41].




6-thioguanine 3.5 ± 0.5 20.5 ± 6.5
6-mercaptopurine 89.7 ± 14.5 22.5 ± 3.6
Theophylline > 4000 1585 ± 134
Caffeine > 4000 2511 ± 156
*Assays were performed with 10 μM tritium labelled hypoxanthine or guanine as su
standard deviation (SD) from at least three independent determinations. P < 0.05 is
nd = not determined.known, and inhibition of TK activity by these two analogs
may account for the observed Mpn growth inhibition.
Therefore, we determined the IC50 values for TFT and
5FdU with dT as a substrate and found significant differ-
ences in IC50 values between TFT and 5FdU for all en-
zymes. TFT inhibited dT phosphorylation in Mpn protein
extracts with an IC50 value of 9.1 ± 2.9 μM, which was
similar to that of recombinant Ureaplasma TK. With
recombinant human TK1 and TK2, the IC50 values were
9.7 ± 3.2 μM and 80 ± 5.6 μM, respectively. The inhib-
ition by 5FdU was much weaker for all recombinant
enzymes and Mpn extracts (Table 5). Thus, TFT was a
significantly better inhibitor than 5FdU.
Discussion
Mycoplasmas differ from their hosts in the biosynthesis
of precursors for DNA and RNA because they cannot
synthesize purine and pyrimidine bases de novo. There-
fore, they rely totally on the salvage pathway for nucleo-
tide biosynthesis (depicted in Figure 4). Purine bases
such as Hx, Gua, and Ade are recycled by HPRT and
adenine phosphoribosyl transferase, whereas the pyr-
imidine base, uracil is salvaged by uracil phosphoribosyl
transferase [31,32]. The salvage of deoxynucleosides is
catalyzed by deoxynucleoside kinases, including TK
and deoxyadenosine/deoxyguanosine kinase [29]. The
deoxynucleoside monophosphates are further phosphory-
lated to their corresponding triphosphates and are used
as precursors for DNA synthesis. The ribonucleoside
monophosphates are further phosphorylated to their tri-
phosphate forms, and are then incorporated into RNA,
or the diphosphate forms can be reduced by ribonucleo-
tide reductase to produce precursors for DNA synthesis
(Figure 4). Of 17 genes involved in nucleotide biosyn-
thesis, 15 are essential [33,34]. Therefore, it has been
suggested that this pathway may be a therapeutic target
for future development of antibiotics [42].
Our screening of 30 FDA-approved anticancer and
antiviral nucleoside analogs revealed seven potent in-
hibitors of Mpn growth with MIC values at clinically
achievable plasma concentrations. Nucleoside and nucleo-
base analogs used in anticancer and antiviral therapy ares*
Guanine
IC50 (μM)
P value Mpn Human P value
0.0107 3.16 ± 0.2 39.8 ± 4 <0.0001
0.0015 281.8 ± 21 25.1 ± 3 <0.0001
nd nd
nd nd
bstrates and various concentrations of the inhibitors. Data were mean ±
considered as significant.
Figure 3 Substrate saturation curves of TFT with human TK2 (A),
human TK1 (B), and Ureaplasma TK (C). Kinetic assays with TFT were
performed by using [γ-32P]-ATP as the labelled substrate at fixed
concentration and variable concentrations of TFT. The reaction
products were separated by thin layer chromatography, and quantified
as described in the experimental procedures. Data are from three
independent measurements and are presented as mean ± SD.
Table 4 Kinetic parameters of trifluorothymidine with







Human TK1 5.9 ± 1.7 0.043 ± 0.003 7.3 ± 1.8
Human TK2 8.8 ± 3.8 0.026 ± 0.003 3.0 ± 0.8
Ureaplasma TK 9.9 ± 5.2 0.055 ± 0.008 5.6 ± 1.5
*Assays were performed using phosphoryl transfer assay with [γ-32P]-labelled
ATP (100 μM) and variable concentrations of TFT (1 – 100 μM). The reaction
products were separated by thin layer chromatography and were quantified.
Thymidine (10 μM) was used as a control. Data are from three independent
measurements and are expressed as mean ± SD.
Table 5 IC50 values (μM) of trifluorothymidine (TFT) and
5-fluorodeoxyuridine (5FdU) with purified recombinant
human TK1 and TK2, Ureaplasma TK, and Mpn extracts*
TFT 5FdU P value
Human TK1 9.7 ± 3.2 75.9 ± 2.6 <0.0001
Human TK2 80 ± 5.6 158.5 ± 2.7 <0.0001
Ureaplasma TK 12.0 ± 4.2 1000 ± 13.3 <0.0001
Mpn extracts 9.1 ± 2.9 47.9 ±1.2 <0.0001
*Assays were performed with 10 μM tritium labelled thymidine as substrate in
the presence of various concentrations of the inhibitors. Data were mean ± SD
from at least three independent determinations. P value < 0.05 is considered
as significant.
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they have to compete with natural substrates for uptake
(e.g. transport across plasma membrane) and metabolism
(e.g. enzymes that activate them to their active forms).Once phosphorylated these analogs are trapped inside the
cells and further metabolized to their active form by cellu-
lar enzymes, therefore, competition/inhibition of enzymes
(e.g. TK or HPRT) in the initial phosphorylation step
would also affect the uptake and metabolism of these
compounds, and thus their cytotoxic effect (Figure 4). As
shown in Table 2, dipyridamole and 6-TG inhibited Hx
and Gua uptake and metabolism but not Ade or Ura,
suggesting that HPRT may be an immediate target. Pyr-
imidine nucleoside analogs e.g. TFT, 5FdU and dFdC
affected the uptake and metabolism of all radiolabeled
substrates, indicating that multiple enzymes/steps are
involved and the extent of uptake of specific nucleoside
or nucleobase is determined by activities of these meta-
bolic enzymes (Figure 4).
The 6-TG inhibited Mpn growth with MIC value of
0.20 μg ml-1, which is equivalent to tetracycline (MIC =
0.1 μg ml-1). However, 6-MP, a 6-TG analog did not
inhibit Mpn growth. Neither theophylline, 7-(2, 3-
dihydroxypropyl) theophylline, allopurinol, nor caffeine
inhibited Mpn growth. 6-TG strongly inhibited uptake
and incorporation of nucleotides derived from Hx and
Gua into DNA and RNA, indicating that the observed
inhibition by 6-TG was both at the level of transport
and metabolism. It is noteworthy that the uptake/
metabolism of Hx and Gua was inhibited by all the
analogs used.
Thiopurines, especially mercaptopurines, are the first
line drugs for the treatment of acute leukemia since
the 1950s. They are also used in the treatment of
Figure 4 Schematic overview of M. pneumoniae nucleotide biosynthesis. Hx, hypoxanthine; Gua, guanine; Ura, uracil; Thy, thymine; dT,
thymidine; dA, deoxyadenosine; dC deoxycytidine; dG, deoxyguanosine; PRPP, phosphoribosyl pyrophosphate; NMP, nucleoside monophosphate;
NDP, nucleoside diphosphate, NTP, nucleoside triphosphate; dNDP, deoxynucleoside diphosphate; dNTP, deoxynucleoside triphosphate; TFT,
trifluorothymidine; TFT-MP, trifluorothymidine monophosphate; TFT-TP, trifluorothymidine triphosphate; 5FdU-MP, 5-fluorodeoxyuridine monophosphate;
5FdU-TP, 5-fluorodeoxyuridine triphosphate; dFdC-DP, gemcitabine diphosphate; dFdC-TP, gemcitabine triphosphate; 6-TG, 6-thioguanine;
6-TG-TP, 6-thioguanine triphosphate. Enzymes: hpt, hypoxanthine guanine phosphoribosyl transferase (MPN672); apt, adenine phosphoribosyl
transferase (MPN395); upp, uracil phosphoribosyl transferase (MPN033); deoA, thymidine phosphorylase (MPN064); tdk, thymidine kinase
(MPN044); thyA, thymidylate synthase (MPN320); tmk, thymidylate kinase (MPN006); adk, adenylate kinase (MPN185); gmk, guanylate kinase
(MPN246); cmk, cytidylate kinase (MPN476); nrdE/nrdF, ribonucleotide reductase (MPN322 and MPN324); pyrH, uridylate kinase (MPN632);
deoxyadenosine kinase (MPN386). I = inhibition.
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exert their cytotoxicity through incorporation into DNA
as deoxy-6-thioguanosine. These thiopurines are metabo-
lized to deoxy-6-thioguanosine triphosphate via the purine
salvage pathway initiated by HPRT (Figure 4). Thiopurine
methyl transferase is a key enzyme in converting mercap-
topurine to its cytotoxic metabolites, which can either in-
hibit purine nucleotide biosynthesis or incorporate into
DNA or RNA, causing DNA damage and cell death [37].
Mpn does not possess the essential enzymes, inosine
monophosphate dehydrogenase and thiopurine methyl
transferase, to convert mercaptopurine to the cytotoxic
thioguanine nucleotides, the respective methyl thiopurine
nucleotides. This may explain why 6-MP did not inhibit
Mpn growth.
To further investigate the mechanism by which 6-TG
inhibited Mpn growth, Mpn HPRT was expressed, puri-
fied, and characterized. Both Hx and Gua are good sub-
strates for the enzyme and the Vmax values for these
substrates are in the same order of magnitude as the hu-
man enzyme [44]. In humans, the plasma concentrations
of Hx and Gua are approximately 172 μM and 97 μM
[45], which is close to the Km and S0.5 values of Mpn
HPRT with Hx and Gua. These results suggest that Mpn
HPRT is capable of efficiently salvaging both Hx and Gua.
In addition, Mpn HPRT showed positive cooperativitywith Gua, indicating that at higher Gua concentration the
enzyme utilizes Gua better.
6-TG and 6-MP are structural analogs. The observed
significant differences in their inhibitory effects with Mpn
and human HPRT suggest that there are structural differ-
ences in binding of these two compounds to the respective
HPRTs in their active sites. These differences could be
used in future design of Mycoplasma specific inhibitors.
HPRT has been suggested as a target for anti-parasite
drug development and new compounds have been
developed [46].
Halogenated pyrimidine analogs such as 5FdU inhibited
Mpn and Ureaplasma growth, as reported in our earlier
studies [30,35]. Others have shown that TFT and 5FdU
inhibited Cryptosporidium growth [47], and gemcitabine
inhibited Staphylococcus aureus growth in vitro and in
animal models [48]. In this study, several halogenated
pyrimidine analogs inhibited Mpn growth, and TFT and
dFdC were more potent than 5FdU. The mechanism of
inhibition by dFdC is most likely due to inhibition of
ribonucleotide reductase and incorporation into DNA
by dFdC metabolites (Figure 4). We did not observe
significant differences in the inhibitory effects between
the wild type and the thyA mutant strains, suggesting
that TS activity is not required for toxicity of these
compounds to Mpn.
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http://www.biomedcentral.com/1471-2180/13/184Mycoplasma TK is an essential enzyme while TS is not
[31,33,34]. The expression of TK in Mpn was correlated
with Mpn growth and DNA synthesis, and upregulation
of TK activity was observed in an Mpn strain lacking TS
activity [31]. The phosphorylated products of TFT and
5FdU by TK irreversibly inhibit TS activity via covalent
binding to the enzyme, and down regulation of TS activity
leads to upregulation of TK activity, similar to what was
observed with the thyA mutant [31]. Increased salvage
of dT due to the induction of TK activity leads to higher
level of dTTP, an allosteric regulator of purine nucleo-
tide reduction by ribonucleotide reductase. Inhibition of
ribonucleotide reductase activity by high level of dTTP
led to decreased uptake and incorporation of labelled
nucleobases as shown in this study, which may result in
imbalance in nucleotide pools. In addition, high TK ac-
tivity facilitates the phosphorylation of TFT and 5FdU
and accumulation of TFT-TP and 5FdUTP that may
affect the integrity of DNA and lead eventually to cell
death (Figure 4). The fact that both TFT and 5FdU
inhibited the growth of both wild type and the thyA
mutant strain to the same extent, and the TK activity
is upregulated by TFT and 5FdU, suggests that TK plays
an important role in growth inhibition observed with
these compounds.
Conclusions
In this study we have shown that several anticancer and
antiviral nucleoside and nucleobase analogs are potent
inhibitors of Mpn growth and that the plausible mech-
anism of growth inhibition by these analogs are due to
inhibition of enzymes in the nucleotide biosynthesis
pathway and nucleoside transporter. We should keep in
mind that the analogs used in this study are potent anti-
cancer and antiviral drugs and most of them have di-
verse adverse side effect in humans and therefore, they
may not be suitable for treatment of a mild Mpn infection.
However, the results obtained with these analogs may be
used as leads in the design of Mycoplasma specific inhibi-
tors, substrates, or non-substrate inhibitors for the target
enzymes in order to reduce the risk of host cell toxicity.
More work regarding the mechanism of action of these
drugs is needed. This study has provided the basis for




Radiolabelled substances: [3H]-hypoxanthine ([3H]-Hx,
13.8 Ci/mmol), [3H]-thymidine ([3H]-dT, 20 Ci/mmol),
[γ-32P]-ATP (2000 Ci/mmol), [3H]-Uracil ([3H]-Ura, 31.65
Ci/mmol), and [3H]-adenine ([3H]-Ade, 27.2 Ci/mmol) were
purchased from PerkinElmer. [3H]-guanine ([3H]-Gua, 10.7
Ci/mmol) and [5-3H]-deoxyuridine 5’-monophosphate ([3H]-dUMP, 27 Ci/mmol) were from Moravek Biochemicals, Inc.
The nucleoside and nucleobase analogs library [36] was
kindly provided by Professor Pär Nordlund, from the
Karolinska Institute, Stockholm, Sweden. Phosphoribosyl
pyrophosphate (PRPP), dipyridamole, tetracycline, and
nonradioactive Hx and Gua were from Sigma-Aldrich.
Mpn culture, and the effects of nucleoside and
nucleobase analogs on growth and metabolism
Nucleoside and nucleobase analogs were dissolved in di-
methyl sulfoxide (DMSO) as stock solutions and diluted
with Mpn culture medium to the desired concentration
immediately prior to use. The DMSO concentration in
the final dilution was < 1%, which would not interfere
with Mpn growth.
Mpn laboratory strain M129 wild type and a thyA
mutant strain [31] were used in this study. Mpn was
cultured at 37°C in a CO2 incubator using 75 cm
2 tissue
culture flasks containing 50 ml Hayflick’s medium, and
harvested at day 4 when the medium color change was
observed [49]. The cells were harvested and the pellet was
resuspended in 6 ml fresh medium and the cfu/ml was
determined by serial dilution (10-fold) and plating on
broth agar plate. Colonies was counted and cfu/ml was
calculated.
Inhibition studies were performed in 96-well plates
containing 200 μl Mpn culture (approximately 106 cfu ml-1)
in Hayflick’s medium and 200 μl each compound in series
dilutions (2-fold) with the growth medium, with three to
four replicas. The plates were sealed with clear adhesive
sheets and incubated at 37°C incubator. Absorbance ratio
at 450 nm and 560 nm was used as Mpn growth index,
which was measured daily, and by visual detection for at
least 8 days, as previously described [32]. In the absence
of inhibitor, the culture medium turned yellow on day 4.
Controls were cultured in the presence of 2 μg/ml tetra-
cycline, which showed no growth for up to 8 days.
Medium was placed in four wells per plate for controls,
which showed no color change during the incubation
period. The MICs (minimal inhibitory concentration re-
quired to inhibit Mpn growth to 90%) were determined
as the lowest concentration at which the growth index
was ≈ 10% of the control values (at the time when the
control culture medium color turned yellow), essentially
as described [50].
Nucleoside and nucleobase uptake and metabolism
was done with the wild type strain, which was cultured
in 25 cm2 tissue culture flasks, inoculated with 1 ml stock
culture (1 × 108 cfu/ml) Mpn, in the presence of tritium
labeled dT, Hx, Gua, Ade or Ura (1 μCi ml-1) and the
presence or absence of nucleoside and nucleobase analogs
(10 μM) and incubated at 37°C for 70 hours. The cells
were harvested and analyzed essentially as described [31].
Analogs used were dipyridamole, 6-thioguanine (6-TG),
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http://www.biomedcentral.com/1471-2180/13/184trifluorothymidine (TFT), gemcitabine (dFdC) and 5-
fluorodeoxyuridine (5FdU). Total uptake is the percent
of radioactivity recovered in the cells divided by total
radioactivity added to the growth medium. Percent of
acid insoluble (radioactivity found in DNA and RNA)
was also calculated [31]. These experiments were done
more than three times and data are given as mean ± SD.
To determine the effect of TFT on TK and TS activity,
Mpn wild type cells were cultured in 75 cm2 tissue
culture flasks containing 50 ml medium, inoculated
with 3 ml of stock culture (1 × 109 cfu/ml), in the
presence of [3H]-dT (1 μCi ml-1) and different concen-
trations of TFT. After 70 hours at 37°C the cultures
were harvested and divided to two aliquots, one was
used to determine total uptake/metabolism of radiolabeled
dT and total proteins were extracted from the other
aliquot and used to measure TK and TS activity using
[3H]-dT and [5-3H]-dUMP as substrates [31].Expression and purification of recombinant Mpn HPRT
The Mpn HPRT gene (MPN672) coding sequence was
codon optimized for expression of the recombinant pro-
tein in E. coli, by using the Proprietary OptimumGene™
codon optimization technology combined with gene
synthesis (GenScript Inc.), and the synthetic cDNA was
then cloned into the pEXP5NT vector (Invitrogen), and
expressed as an N-terminal fusion protein with a 6xHis
tag and a TEV cleavage site. The plasmid containing the
MPN672 gene was then transformed into the BL21
(DE3) pLysS strain and the recombinant protein produc-
tion was induced by addition of 0.1 mM IPTG at 37°C for
4 h. The cells were harvested by centrifugation at 2000 × g
for 25 min at 4°C. The pellets were resuspended in lysis
buffer containing 25 mM Tris/HCl, pH 7.5, 2 mM MgCl2,
and 0.4 M NaCl. The cells were lysed by repeated freezing
and thawing, and sonication for 2 min in an ice/water
bath. After centrifugation at 25,000 × g for 30 min at 4°C,
the supernatant was used to purify the recombinant pro-
tein by metal affinity chromatography on a Ni-Sepharose
(GE Healthcare) resin column, and the Mpn HPRT was
eluted with 0.4 M imidazole in lysis buffer. The eluted
fractions were analyzed by 12% SDS-PAGE and those
containing purified enzyme were pooled and passed
through a PD-10 column (GE Healthcare) for desalting
and buffer exchange. The final enzyme preparation was
in a buffer containing 10 mM Tris/HCl, pH 7.5, 5 mM
MgCl2, 1 mM dithiothreitol (DTT), and 20% glycerol,
and stored in aliquots at −70°C. Protein concentration
was determined by Bio-Rad protein assay using bovine
serum albumin (BSA) as a standard.
Recombinant human TK1, human TK2, Ureaplasma
TK, and human HPRT were expressed and purified as
previously described [30,40,44,51].Enzyme assays
The HPRT assay was performed by using the DE-81
filter paper assay with tritium labeled hypoxanthine
([3H]-Hx) or guanine ([3H]-Gua) as substrates, essen-
tially as previously described [44]. Briefly, the reaction
mixture contained 50 mM Tris/HCl, pH 7.5, 10 mM
MgCl2, 5 mM DTT, 15 mM NaF, 1 mM PRPP, and
various concentrations of [3H]-Hx or [3H]-Gua in a
total of 50 μl. The reaction was initiated by addition
of the enzyme, and at 0, 5, 10, and 15 min intervals,
10 μl reaction mixture was withdrawn and spotted onto
the DE81 filter paper and dried. The unreacted substrate
was washed and the products were eluted and counted in
a liquid scintillation counter. With [3H]-Gua as substrate
the reaction (in a total of 25 μl) was initiated by addition
of the enzyme (10 μl), incubated at 37°C for 2 min,
stopped by addition of 1 M HCl (10 μl), and placed imme-
diately on ice. After neutralization, 15 μl of the mixture
was spotted onto the DE81-filter paper. The filters were
then washed, and the products were eluted and counted
by liquid scintillation.
IC50 values for purine analogs were determined for
both Mpn HPRT and human HPRT using fixed concen-
trations of [3H]-Hx (10 μM) or [3H]-Gua (10 μM) and
variable concentrations of the inhibitors.
Thymidine kinase assay was performed using tritium
labelled thymidine ([3H]-dT) as substrate and various
concentrations of the inhibitors essentially as previously
described [40] to determine the IC50 values of TFT and
5FdU.
Kinetic parameters for TFT were determined by using
the phosphoryl transfer assays as previously described
[52]. Briefly, each reaction was performed in a total volume
of 20 μl containing 50 mM Tris/HCl, pH 7.5, 0.5 mg/ml
BSA, 5 mM DTT, 2 mM MgCl2, 15 mM NaF, variable
concentrations of TFT, 0.1 mM [γ-32P]-ATP, and 50 ng
purified enzyme at 37°C for 20 min, and stopped by
heating at 70°C for 2 min. After brief centrifugation,
1 μl supernatant was spotted onto a TLC plate (PEI-
cellulose, Merck) and dried. The TLC plates were de-
veloped in isobutyric acid/ammonia/H2O (66:1:33). The
reaction products were visualized and quantified by
phosphoimaging analysis (Quantity One, Bio-Rad).
Statistical analysis
The data were analysed by unpaired student’s t-test (two
tailed) using GraphPad Prism 5 software. P < 0.05 is con-
sidered as significant.
Competing interests
Both authors declare that they have no competing interests.
Authors’ contributions
RS performed the kinetic and inhibitions studies with thymidine kinases,
analyzed the data and created the figures; LW designed the study,
performed growth inhibition studies, uptake and metabolism of labelled
Sun and Wang BMC Microbiology 2013, 13:184 Page 11 of 12
http://www.biomedcentral.com/1471-2180/13/184nucleosides, characterized Mpn HPRT; analyzed the data and wrote the
manuscript. All authors have read and approved the manuscript.Acknowledgements
This work was supported by a grant from the Swedish Research Council for
Environment, Agricultural Sciences, and Spatial Planning. We thank Professor
Pär Nordlund, Karolinska Institute, Stockholm, for providing the nucleoside
and nucleobase analogs.
Received: 11 April 2013 Accepted: 24 July 2013
Published: 6 August 2013References
1. Razin S, Yogev D, Naot Y: Molecular biology and pathogenicity of
Mycoplasmas. Microbiol Mol Biol Rev 1998, 62:1094–1156.
2. Waites KB, Talkington DF: Mycoplasma pneumoniae and its role as a
human pathogen. Clin Microbiol Rev 2004, 17:697–728.
3. Narita M: Pathogenesis of extrapulmonary manifestations of Mycoplasma
penumoniae infection with special reference to pneumonia. J infec
Chemother 2010, 16:162–169.
4. Lenglet A, Herrado Z, Magiorakos A, Leitmeyer K, Coulombier D:
Surveillance status and recent data for Mycoplasam pneumoniae
infection in the European Union and European Economic area, January
2012. Euro Surveill 2012, 17:2–7.
5. Pereyre S, Renaudin H, Charron A, Bebear C: Clonal spread of Mycoplasma
pneumoniae in primary school, Bordeaux, France. Emerg Infect Dis 2012,
18:343–345.
6. Lung D, Chan Y, Kwong L, Que T: Severe community-acquired pneumonia
caused by macrolide-resistant Mycoplasma pneumoniae in a 6-year-old
boy. Hong Kong Med J 2011, 17:407–409.
7. Hsieh Y, Tsao K, Huang C, Tong S, Winchell J, Huang Y, Shia S, Lai S, Lin T:
Life-threatening pneumonia caused by macrolide-resistant Mycoplasma
pneumoniae. Pediatr Infect Dis 2012, 31:208–209.
8. Morozumi M, Takahashi T, Ubukata K: Macrolide-resistant Mycoplasma
pneumoniae: characteristics of isolates and clinical aspects of
community-acquired pneumonia. J Infec Chemother 2010, 16:78–86.
9. Bebear C, Pereyre S, Peuchant O: Mycoplasma pneumoniae: susceptibility
and resistance to antibiotics. Future Microbiol 2011, 6:423–431.
10. Yamada M, Buller R, Bledsoe S, Storch G: Rising rates of macrolode-resistant
Mycoplasma pneumoniae in the central United State. Pediatr Infect Dis
2012, 31:409.
11. Zhao F, Lv M, Tao X, Huang H, Zhang B, Zhang Z, Zhang J: Antibiotic
sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis
of macrolide-resistant isolates from Beijing, China. Antimicrob Agents
Chemother 2012, 56:1108–1109.
12. Cao B, Zhao C, Yin Y, Zhao F, Song S, Bai L, Zhang J, Liu Y, Zhang Y, Wang H,
Wang C: High prevalence of macrolide resistance in Mycoplasma
pneumoniae isolates from adult and adolescent patients with respiratory
tract infection in China. Clin Infect Dis 2010, 51:189–194.
13. Scozzafava A, Owa T, Mastrolorenzo A, Supuran C: Anticancer and antiviral
sulfonamides. Curr Med Chem 2003, 10:925–953.
14. Jackman A, Calvert A: Folate-based thymidylate synthase inhibitors as
anticancer drugs. Ann Oncol 1995, 6:871–881.
15. Costi M, Tondi D, Rinaldi M, Barlocco D, Pecorari P, Soragni F, Venturelli A,
Stroud R: Structure-based studies on species-specific inhibition of
thymidylate synthase. Biochim Biophys Acta 2002, 1587:206–214.
16. Lee W, Martin J: Perspectives on the development of acyclic nucleoside
analogs as antiviral drugs. Antiviral Res 2006, 71:254–259.
17. Arts E, Hazuda D: HIV-1 antiretroviral drug therapy. Cold Spring Harb
Perspect Med 2012, 2:1–23.
18. Carnrot C, Vogel S, Byun Y, Wang L, Tjarks W, Eriksson S, Phipps A:
Evaluation of Bacillus anthracis thymidine kinase as a potential target for
the development of antibacterial nucleoside analogs. Biol Chem 2006,
387:1575–1581.
19. Srivastava R, Bhargava A, Singh R: Synthesis and antimicrobial activity of
some novel nucleoside analogues of adenosine and 1,3-
dideazaadenosine. Bioorg Med Chem Lett 2007, 17:6239–6244.
20. Van Calenberg S, Pochet S, Munier-Lehmann H: Drug design and
identification of potent leads against Mycobacterium tuberculosis
thymidine monophosphate kinase. Curr Top Med Chem 2012, 12:694–705.21. Choi J, Plummer M, Starr J, Desbonnet C, Soutter H, Chang J, Miller J,
Dillman K, Miller A, Roush W: Structure guided development of novel
thymidine mimetics targeting Pseudomonas aeruginosa thymidylate
kinase: from hit to lead generation. J Med Chem 2012, 55:852–870.
22. Martinez-Botella G, Breen J, Duffy J, Dumas J, Geng B, Gowers I, Green O,
Guler S, Hentemann M, Hernandez-Huan F, Joseph-McCarthy D, Kawatkar S,
Larsen N, Lazari O, Loch J, Macritchie J, McKenzie A, Newman J, Olivier N,
Otterson L, Owens A, Read J, Sheppard D, Keating T: Discovery of selective
and potent inhibitors of gram-positive bacterial thymidylate kinase
(TMK). J Med Chem 2012, 55:10010–10021.
23. Keating T, JV N, Olivier N, Otterson L, Andrews B, Boriack-Sjodin P, Breen J,
Dolg P, Dumas J, Gangl E, Green O, Guler S, Hentemann M, Joseph-McCarthy D,
Kawatkar S, Kutschke A, Loch J, McKenzie A, Pradeepan S, Prasad S,
Martinez-Botella G: In vivo validation of thymidylate kinase (TMK) with a
rationally designed, selective antibacterial compound. ACS Chem Biol
2012, 7:1866–1872.
24. Mitchell A, Finch L: Pathways of nucleotide biosynthesis in Mycoplasma
mycoides subsp. mycoides. J Bacteriol 1977, 130:1047–1054.
25. Mitchell A, Sin I, Finch L: Enzymes of purine metabolism in Mycoplasma
mycoides subsp. mycoides. J Bacteriol 1978, 134:706–712.
26. Mitchell A, Finch L: Enzymes of pyrimidine metabolism in Mycoplasma
mycoides subsp. mycoides. J Bacteriol 1979, 137:1073–1080.
27. Pollack J, Williams M, Banzon J, Jones M, Harvey L, Tully J: Comparative
metabolism of Mesoplasma, Entomoplasma, Mycoplasma, and
Acholeplasma. Int J Syst Bacteriol 1996, 46:885–890.
28. Pollack J, Williams M, McElhaney R: The comparative metabolism of the
Mollicutes (Mycoplasmas): the utility for taxonomic classification and the
relationship of putative gene annotation and phylogeny to enzymatic
function in the smallest free-living cells. Crit Rev Microbiol 1997,
23:269–354.
29. Wang L, Westberg J, Bölske G, Eriksson S: Novel deoxynucleoside-
phosphorylating enzymes in Mycoplasmas: evidence for efficient
utilization of deoxynucleosides. Mol Microbiol 2001, 42:1065–1073.
30. Carnrot C, Wehelie R, Eriksson S, Bölske G, Wang L: Molecular
characterization of thymidine kinase from Ureaplasma urealyticum:
nucleoside analogues as potent inhibitors of mycoplasma growth.
Mol Microbiol 2003, 50:771–780.
31. Wang L, Hames C, Schmidt S, Stülke J: Upregulation of thymidine kinase
activity compensates for loss of thymidylate synthase activity in
Mycoplasma pneumoniae. Mol Microbiol 2010, 77:1502–1511.
32. Yus E, Maier T, Michalodimitrakis K, van Noort V, Yamada T, Chen W, Wodke J,
Güell M, Martinez S, Bourgeois R, Kühner S, Raineri E, Letunic I, Kalinina O,
Rode M, Herrmann R, Gutierrez-Gallego R, Russell R, Gavin A, Bork P,
Serrano L: Impact of genome reduction on bacterial metabolism and its
regulation. Science 2009, 326:1263–1268.
33. Hutchison C, Peterson S, Gill S, Cline R, White O, Fraser C, Smith HO, Venter JC:
Global transposon mutagenesis and a minimal Mycoplasma genome.
Science 1999, 286:2165–2169.
34. Glass JI, Assad-Garcia N, Alperovich N, Yooseph S, Lewis MR, Maruf M,
Hutchison CA, Smith HO, Venter JC: Essential genes of a minimal
bacterium. Proc Natl Acad Sci USA 2006, 103:425–430.
35. Wehelie R, Eriksson S, Bölske G, Wang L: Growth inhibition of Mycoplasma
by nucleoside analogues. Nucleosides, Nucleotides & Nucleic Acid 2004,
23:1499–1502.
36. Egeblad L, Welin M, Flodin S, Gräslund S, Wang L, Balzarini J, Eriksson S,
Nordlund P: Pan-pathway based interaction profiling of FDA-approved
nucleoside and nucleobase analogs with enzymes of the human
nucleotide metabolism. PLoS One 2012, 7:e37724.
37. Hindorf U, Lindqvist M, Peterson C, Söderkvist P, Ström M, Hjortswang H,
Pousette A, Almer S: Pharmacogenetics during standardised initiation of
thiopurine treatment in inflammatory bowel disease. Gut 2006,
55:1423–1431.
38. Santi D, Sakai T: Thymidylate synthetase. Model studies of inhibition by
5-trifluoromethyl-2'-deoxyuridylic acid. Biochemistry 1971, 10:3598–3607.
39. Welin M, Kosinska U, Mikkelsen N, Carnrot C, Zhu C, Wang L, Eriksson S,
Munch-Petersen B, Eklund H: Structures of thymidine kinase 1 of human
and mycoplasmic origin. Proc Natl Acad Sci USA 2004, 101:17970–17975.
40. Wang L, Munch-Petersen B, Herrström Sjöberg A, Hellman U, Bergman T,
Jörnvall H, Eriksson S: Human thymidine kinase 2: molecular cloning and
characterisation of the enzyme activity with antiviral and cytostatic
nucleoside substrates. FEBS Lett 1999, 443:170–174.
Sun and Wang BMC Microbiology 2013, 13:184 Page 12 of 12
http://www.biomedcentral.com/1471-2180/13/18441. Wang J, Su C, Neuhard J, Eriksson S: Expression of human mitochondrial
thymidine kinase in Escherichia coli: correlation between the enzymatic
activity of pyrimidine nucleoside analogues and their inhibitory effect
on bacterial growth. Biochem Pharmacol 2000, 59:1583–1588.
42. Pachkov M, Dandekar T, Korbel J, Bork P, Schuster S: Use of pathway
analysis and genome context methods for functional genomics of
Mycoplasma pneumoniae nucleotide metabolism. Gene 2007, 396:215–225.
43. Ding L, Zhang F, Liu H, Gao X, Bi H, Wang XQ, Chen B, Zhang Y, Zhao L,
Zhong G, Hu P, Chen M, Huang M: Hypoxanthine guanine
phosphoribosyltransferase activity is related to 6-thioguanine nucleotide
concentrations and thiopurine-induced leikopenia in the treatment of
inflammatroy bowel disease. Inflamm Bowel Dis 2012, 18:63–73.
44. Welin M, Egeblad L, Johansson A, Stenmark P, Wang L, Flodin S, Nyman T,
Trésaugues L, Kotenyova T, Johansson I, Eriksson S, Eklund H, Nordlund P:
Structural and function studies of the human phosphoribosyltransferase
domain containing protein 1. FEBS J 2010, 277:4920–4930.
45. Traut T: Physiological concentrations of purines and pyrimidines. Mol Cell
Biochem 1994, 140:1–22.
46. Cesnek M, Hockova D, Holy A, Dracinsky M, Baszczynski O, Jersey J, DT K,
Guddat L: Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl
purines: evaluation of their ability to act as inhibitors of Plasmodium
falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine)
phosphoribosyltransferases. Bioorg Med Chem 2012, 20:1076–1089.
47. Sun X, Sharling L, Muthalagi M, Mudeppa D, Pankiewicz K, Felczak K, Rathod P,
Mead J, Striepen B, Hedstrom L: Prodrug activation by Cryptosporidium
thymidine kinase. J Biol Chem 2010, 285:15916–15922.
48. Sandrini M, Shannon O, Clausen A, Björck L, Piskur J: Deoxyribonucleoside
kinases activate nucleoside antibiotics in severely pathogenic bacteria.
Antimicrob Agents Chemother 2007, 51:2726–2732.
49. Halbedel S, Stülke J: Dual phosphorylation of Mycoplasma pneumoniae
HPr by enzyme I and HPr kinase suggests an extended phosphoryl
group susceptibility of HPr. FEMS Microbiol Lett 2004, 247:193–198.
50. Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri Y, Sasaky Y,
Arakawa Y, Sasaky T: Characteristics of macrolide-resistant Mycoplasma
pneumoniae strains isolated from patients and induced with
erythromycin in vitro. Microbiol Immunol 2001, 45:617–620.
51. Sharif H, von Euler H, Westberg S, He E, Wang L, Eriksson S: A sensitive and
kinetically defined radiochemical assay for canine and human serum
thymidine kinase 1 (TK1) to monitor canine malignant lymphoma. Vet J
2012, 194:40–47.
52. Wang L: The role of Ureaplasma nucleoside monophosphate kinases in
the synthesis of nucleoside triphosphates. FEBS J 2007, 274:1983–1990.
doi:10.1186/1471-2180-13-184
Cite this article as: Sun and Wang: Inhibition of Mycoplasma
pneumoniae growth by FDA-approved anticancer and antiviral
nucleoside and nucleobase analogs. BMC Microbiology 2013 13:184.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
